GIP Receptor Antagonist, SKL-14959 Indicated Alteration of the Lipids Metabolism to Catabolism by the Inhibition of Plasma LPL Activity, Resulting in the Suppression of Weight Gain on Diets-Induced Obesity Mice.

Nakamura, Takashi; Tanimoto, Hitomi; Okamoto, Masayuki; Takeuchi, Mitsuaki; Tsubamoto, Yoshiharu; Noda, Hitoshi

Nakamura, Takashi; Tanimoto, Hitomi; Okamoto, Masayuki; Takeuchi, Mitsuaki; Tsubamoto, Yoshiharu; Noda, Hitoshi.

Afiliação

Nakamura T; Biological Research Group Drug Discovery Laboratories, Sanwa Kagaku Kenkyusho, Mie, Japan.
Tanimoto H; Biological Research Group Drug Discovery Laboratories, Sanwa Kagaku Kenkyusho, Mie, Japan.
Okamoto M; Biological Research Group Drug Discovery Laboratories, Sanwa Kagaku Kenkyusho, Mie, Japan.
Takeuchi M; Biological Research Group Drug Discovery Laboratories, Sanwa Kagaku Kenkyusho, Mie, Japan.
Tsubamoto Y; Biological Research Group Drug Discovery Laboratories, Sanwa Kagaku Kenkyusho, Mie, Japan.
Noda H; Biological Research Group Drug Discovery Laboratories, Sanwa Kagaku Kenkyusho, Mie, Japan.

Diabetes Metab Syndr Obes ; 14: 1095-1105, 2021.

Article em En | MEDLINE | ID: mdl-33727843

Palavras-chave

GIP; GIP receptor antagonist; anti-obesity; lipase activity; lipid metabolism

Texto completo

Adicionar na Minha BVS

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Idioma: En Revista: Diabetes Metab Syndr Obes Ano de publicação: 2021 Tipo de documento: Article País de afiliação: Japão País de publicação: Nova Zelândia

Texto completo

Adicionar na Minha BVS

Imprimir

XML

PubMed Links

Buscar no Google